# Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC

> **NCT04997382** · PHASE2 · COMPLETED · sponsor: **Hunan Province Tumor Hospital** · enrollment: 112 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab
- **DRUG:** Chemotherapy alone or Chemotherapy with or without Bevacizumab

## Key facts

- **NCT ID:** NCT04997382
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-17
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04997382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04997382, "Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04997382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*